Other languages Zai Lab Limited BOERSE MUENCHEN

Equities

1ZL

US98887Q1040

Market Closed - BOERSE MUENCHEN Other stock markets 01:13:02 06/07/2024 am IST			After market 01:30:01 am
15.9 ^EUR	+1.27%		15.95	+0.31%

27/06	Zai Lab Insider Sold Shares Worth $428,532, According to a Recent SEC Filing	MT
20/06	Zai Lab Grants ADSs to Independent Directors Under Incentive Scheme	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Zai Lab Insider Sold Shares Worth $428,532, According to a Recent SEC Filing	28/06
Zai Lab Grants ADSs to Independent Directors Under Incentive Scheme	20/06
Asian Equities Traded in the US as American Depositary Receipts Trend Lower in Friday Trading	14/06
Zai Lab Limited Announces Executive Changes, Effective June 30, 2024	12/06
Tech, Financial Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Sharply Lower Tuesday	04/06
Asian Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Lower	24/05
Zai Lab Doses First Patient in a Phase 2 Clinical Trial of Plaque Psoriasis Treatment; Shares Rise	22/05
Zai Lab Limited Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis	22/05
Chinese Regulator Approves Zai Lab’s New Drug Application for Bacterial Pneumonia Drug	20/05
Zai Lab, Innoviva Subsidiary Receive China Approval for Hospital Infection Treatment	20/05
Zai Lab and Innoviva Specialty Therapeutics Announces NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China	20/05
Asian Equities Traded in the US as American Depositary Receipts Ease in Thursday Trading	16/05
Zai Lab's Supplemental Application for Autoimmune Disease Treatment Accepted by China Regulator	14/05
Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy in China	14/05
Asian Equities Traded in the US as American Depositary Receipts Begin Week Higher	13/05
Zai Lab Says China Approves New Drug Application for Lung Cancer Treatment Augtyro	13/05
Zai Lab Limited Announces Approval of AUGTYRO (repotrectinib) for Patients with ROS1-positive NSCLC by China?s NMPA	13/05
Zai Lab's Shares Rise After Q1 Beat	09/05
Asian Equities Traded in the US as American Depositary Receipts Trend Lower Thursday	09/05
Top Premarket Gainers	09/05

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Zai Lab Limited BOERSE MUENCHEN

Equities

1ZL

US98887Q1040

Other languages

Filters